John C. Byrd
0000-0002-8778-1000
4 papers found
Refreshing results…
First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes
The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation
Missing publications? Search for publications with a matching author name.